SS Innovations International, Inc. has provided an update on its first quarter 2025 performance and commentary on second quarter 2025 order trends. During the first quarter of 2025, the company installed 14 SSI Mantra Surgical Robotic Systems, bringing the cumulative installed base to 78 as of March 31, 2025. Additionally, the company expects revenue for the first quarter of 2025 to be approximately $6.4 million with a gross margin of approximately 45%.
As of April 30, 2025, 80 SSI Mantra Robotic Surgical Systems have been installed in 75 hospitals, and over 3800 surgeries have utilized the SSI Mantra, including over 200 robotic cardiac surgeries. In terms of order trends, SSI Mantra Robotic Surgical System orders totaled 9 in the first month of the second quarter, April 2025, representing a significant increase of 200% from the 3 orders in April 2024.
The company's Chairman of the Board and Chief Executive Officer, Dr. Sudhir Srivastava, expressed confidence in the growth trajectory of the business following the recent uplisting to NASDAQ. The company anticipates reporting its first quarter 2025 financial results on or about May 15, 2025.
SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the proprietary "SSI Mantra" surgical robotic system and the comprehensive suite of "SSI Mudra" surgical instruments, designed to support a variety of surgical procedures, including robotic cardiac surgery. The company, headquartered in India, plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Following these announcements, the company's shares moved 1.3%, and are now trading at a price of $10.65. For the full picture, make sure to review SS Innovations International's 8-K report.
